menu
    • menu

    Company profile for NurrOn Pharmaceuticals

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders. NurrOn is focused on discovering and developing innovative treatments that have the potential to improve clinical outcomes in PD patients. The greatest unmet medical need in PD is to slow or prevent disease...
    NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders. NurrOn is focused on discovering and developing innovative treatments that have the potential to improve clinical outcomes in PD patients. The greatest unmet medical need in PD is to slow or prevent disease progression. Through targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, we aim to develop a paradigm-changing PD treatment to improve patient's quality of life.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NurrOn PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    299 Lexington Street Suite 112 Woburn, MA 01801
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nurronpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HanAll, Daewoong, NurrOn Complete 1st-in-Human Parkinson’s Study
    HanAll, Daewoong, NurrOn Complete 1st-in-Human Parkinson’s Study

    25 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-announce-successful-completion-of-a-first-in-human-study-for-potential-disease-modifying-therapy-for-parkinsons-disease-302315158.html

    PR NEWSWIRE
    25 Nov 2024
    Share Share
    HanAll, Daewoong and NurrOn to Showcase Ongoing Parkinson's Disease Program
    HanAll, Daewoong and NurrOn to Showcase Ongoing Parkinson's Disease Program

    20 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-to-showcase-ongoing-parkinsons-disease-program-at-the-7th-annual-sachs-associates-neuroscience-innovation-forum-302019893.html

    PR NEWSWIRE
    20 Dec 2023
    Share Share
    NurrOn Pharma Incorporated Appoints Dr. Almira Chabi to Board of Directors
    NurrOn Pharma Incorporated Appoints Dr. Almira Chabi to Board of Directors

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hanall-biopharmas-partner-nurron-pharmaceuticals-incorporated-appoints-dr-almira-chabi-md-egmp-to-board-of-directors-302010850.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search